Metabolic & Incretin Research blend
Retatrutide + Cagrilintide RTCAG
Incretin + amylin blend
Research blend of retatrutide, a GIP, GLP-1 and glucagon triple agonist, and cagrilintide, a long-acting amylin analogue.
Evidence level. Little or no public data, or the exact identity is still being confirmed. For a blend, the rating covers the combination itself; each component has its own profile. About the badges
- Class
- Incretin + amylin blend
- Category
- Metabolic & Incretin
- Type
- Research blend
- Abbreviation
- RTCAG
- Development and regulatory status
- Not approved; both components are investigational
Blend composition
Retatrutide 5 mg + Cagrilintide 5 mg
Each component is profiled separately in the catalogue: Retatrutide, Cagrilintide, CagriSema.
What researchers study
A research blend of retatrutide, a GIP/GLP-1/glucagon triple agonist, and cagrilintide, a long-acting amylin analogue. The components act on separate pathways, incretin and glucagon receptors versus amylin receptors, which makes the pairing of interest for combination pharmacology.
Research areas
- Combined triple-agonist and amylin pathway studies
- Satiety and energy-balance signalling in metabolic models
- Comparing single-agent and combined receptor pharmacology
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- literature check
No published studies of retatrutide combined with cagrilintide were identified
- phase 3 trial
A related amylin plus incretin pairing, cagrilintide with semaglutide, had mean weight change of -20.4% at 68 weeks versus -3.0% with placebo
- phase 2 trial
Cagrilintide alone: -6.0% to -10.8% at 26 weeks across groups versus -3.0% with placebo
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Retatrutidetriple agonist, a component of this blend
- Cagrilintideamylin analogue, a component of this blend
- CagriSemacagrilintide plus semaglutide, the best-studied amylin and incretin pairing
